Ross Mitchell named artificial intelligence officer at Moffitt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ross Mitchell has joined Moffitt Cancer Center as the artificial intelligence officer.

In this new role, he will lead the cancer center’s efforts to develop digital tools and technologies that utilize computer science to improve the efficiency and quality of cancer care.

Mitchell is also a senior member of Moffitt’s Department of Biostatistics and Bioinformatics and will collaborate with fellow research faculty to optimize projects utilizing artificial intelligence applications.

“Data science is a growing area in cancer research and care. Through the analysis of data, we can better predict outcomes to assist with informed decision-making. Mitchell will help Moffitt identify those business and clinical opportunities where predictive analytics, machine learning and other advanced technologies can be used to improve our patient experience,” said Dana Rollison, vice president, chief data officer and associate center director of Data Science at Moffitt. “He will also bring this skillset to our research enterprise.”

Mitchell comes to Moffitt from the Mayo Clinic in Scottsdale, where he led multiple medical imaging informatics initiatives such as the application of machine learning in brain tumor imaging.

Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login